Precision Sales General And Administrative To Revenue from 2010 to 2024
| DTIL Stock | USD 6.50 0.68 9.47% |
Check Precision BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Precision BioSciences' main balance sheet or income statement drivers, such as , as well as many indicators such as . Precision financial statements analysis is a perfect complement when working with Precision BioSciences Valuation or Volatility modules.
Precision |
About Precision BioSciences Financial Statements
Precision BioSciences investors utilize fundamental indicators, such as Sales General And Administrative To Revenue, to predict how Precision Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Precision Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 192 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Precision BioSciences Correlation against competitors. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.